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CHARACTERISTICS OF PATIENTS AND PREDICTORS OF IN-HOSPITAL 
MORTALITY AFTER HOSPITALIZATION FOR LUNG CANCER IN WEST 
VIRGINIA
Nadpara P1, Tworek C2, Madhavan S1
1West Virginia University, Morgantown, WV, USA, 2West Virginia University School of 
Pharmacy, Morgantown, WV, USA
OBJECTIVES: The objectives of this study were to describe the characteristics of 
patients who were hospitalized for lung cancer in West Virginia during the year 2007 
and to identify predictors of in-hospital mortality. METHODS: Study data are drawn 
from 2007 hospital discharge records in the state of West Virginia, using the Agency 
for Health Research and Quality Healthcare Cost and Utilization Project State Inpa-
tient Database (HCUP-SID). All patients who had a primary diagnosis of lung cancer 
were included in the study. Univariate and multivariate logistic regression analyses 
were used to identify patient characteristics that were associated with in-hospital 
mortality. RESULTS: In total, 1326 discharge records with lung cancer as primary 
diagnosis were identiﬁed. The average age of patients was 66 years, the mean length 
of stay in the hospital was 8 days, and the in-hospital mortality rate was 13%. Patients 
who had comorbid conditions and complications and patients who were grouped 
under the self-pay/no charge/ others category had greater odds of in-hospital mortality 
compared with patients who were covered by private insurance (P < 0.05). CONCLU-
SIONS: Patients with comorbid conditions and complications and patients without 
adequate insurance coverage had greater odds of in-hospital mortality. One reason 
for this may be inadequate access to care because of the absence of insurance or 
underinsurance. Further studies controlling for disease stage will be required to deter-
mine whether insurance status and patient-related factors can inﬂuence outcomes from 
lung cancer in individual patients independent of their disease stage.
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THE FINANCIAL EFFECT OF THE INTRODUCTION OF PERFORMANCE-
VOLUME LIMIT (PVL) ON THE HUNGARIAN ONCOLOGY CARE
Boncz I1, Donka-Verebes É2, Oberfrank F3
1University of Pécs, Pécs, Hungary, 2Intergra Consulting Ltd., Budapest, Hungary, 3Institute of 
Experimental Medicine, Budapest, Hungary
OBJECTIVES: Hungary was the ﬁrst country in Europe fully implementing a DRG 
(Diagnosis Related Groups) like ﬁnancing method for the whole hospital care as early 
as 1993. In 2004 in addition to the DRG like ﬁnancing technique, the so-called per-
formance volume limit (PVL) was introduced forming an artiﬁcial ﬁnancial cap for 
the activity based ﬁnancing of the Hungarian hospitals. The aim of our study is to 
analyse the effect of performance-volume limit (PVL) on the performance indicators 
of acute oncology care, with special respect to the health insurance reimbursement 
not paid to health care providers. METHODS: Data were derived from the nationwide 
administrative dataset of the National Health Insurance Fund Administration (OEP) 
covering the period 2006–2008. We analysed the effect of PVL according to medical 
specialities. We calculated the average annual reimbursement rate of DRG cost-weight 
with and without the application of PVL. The loss due to PVL was calculated both 
by monetary terms and as the % of annual revenue. RESULTS: The loss of medical 
specialities measured by monetary units (Hungarian forint, HUF) and as a percent of 
their revenues was the followingin 2008-ban: Oncology 1327 million HUF (4,7%), 
Cardiology 791 million HUF (3,0%), Gynecology and obstetrics 772 million HUF 
(3,0%), internal medicine 708 million HUF (3,3%), intensive care 661 million HUF 
(2,5%), surgery 637 million HUF (3,2%), pediatrics 614 million HUF (3,9%), trau-
matology 545 million HUF (2,5%), radiotherapy 438 million HUF (3,1%). CON-
CLUSIONS: The introduction of performance-volume limit had signiﬁcantly different 
effect on the different medical specialities. Oncology care can be cosidered as one of 
the largest loser of the application of performance-volume limit.
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OPTIMISING MARKET ACCESS FOR ONCOLOGY DRUGS IN BRAZIL  
& CHINA
Dummett H, Shankland B
Double Helix Consulting, London, UK
OBJECTIVES: Brazil & China represent two fast growing markets for oncology 
products. Market access drivers for new oncology brands are not transparent. While 
manufacturers are increasingly pursuing patient access schemes to drive market access 
in developed markets, it is unclear if these will be as applicable in these emerging 
markets. METHODS: A total of 15 payers, payer advisers & price-sensitive customers 
across both public & private sectors in Brazil & China were interviewed in late 2009 
to understand their evidence requirements for new oncology products, and their open-
ness to ﬂexible pricing agreements or patient access schemes RESULTS: The primary 
market for oncology brands in China remains the self-pay hospital market, for which 
critical market access drivers are compelling local efﬁcacy data, the perceived revenue 
opportunity for the dispensing hospital and KOL endorsement. While discounts are a 
vital market access driver at this level, at national level price-volume agreements for 
high-cost oncology brands are being considered for the ﬁrst time as a criterion for 
access to the National Reimbursement Drug List (NRDL), under a pilot negotiation 
scheme. Economic arguments, based on local data, are also becoming more important 
for reimbursement. In Brazil, public payers are most concerned with cost-effectiveness, 
while private payers consider clinical beneﬁt the most important factor in decision-
making. There are no ﬂexible pricing arrangements for oncology products in Brazil, 
but both public & private payers express interest in discounts based on the duration 
of treatment. CONCLUSIONS: Outcomes-based agreements are inappropriate for 
either the Brazilian or Chinese setting due to difﬁculty in implementation and monitor-
ing. However, price-volume deals will be considered, in Brazil in the private sector 
and in China in the public sector. Further development of public PE requirements is 
anticipated in light of recent policy guidance on NRDL revision processes & NICE 
consultancy to the Health Ministry.
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INFLUENCE OF HEALTH TECHNOLOGY ASSESSMENTS ON 
UTILIZATION OF BEVACIZUMAB IN EUROPE
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OBJECTIVES: Prices of recently launched monoclonal antibodies are relatively high 
and their accessibility differs between European countries. Bevacizumab (BVZ) was 
granted full access in Germany and France, but rejected in UK. It was subject in Italy 
to payment by performance with a 50% discount for the ﬁrst 6 weeks and free after 
11 to 15 cycles. In France BVZ is reimbursed to hospitals on top of DRG costs. 
METHODS: We reviewed how such differences might affect usage of BVZ in France, 
Germany, Italy and UK. Data on drug utilization from June 2006 to July 2009 were 
extracted from the Synovate Oncology Monitor, an ongoing database tracking pre-
scribing of anti-cancer therapies for patients within and across tumours over time. 
Total sample size varied between countries, from 7,766 to 9,463 patients within the 
year ending 2009 Q2. RESULTS: Metastatic colorectal cancer (mCRC) represents the 
ﬁrst indication for BVZ, accounting for 62% of usage in France, 56% in Germany, 
and 75% in Italy. Proportions of mCRC patients receiving BVZ were 18%, 14% and 
21% in France, Germany and Italy, over the period Jul 08-Jun 09. Utilization rates 
for other tumours (breast, renal cell, brain and non-small cell lung cancer) ranged 
from 1% to 6% in France, Germany and Italy. Over the three-year period, overall 
utilization was stable in France, increased slowly in Germany and faster in Italy. In 
the UK, BVZ was prescribed to fewer than 1% of patients for all tumours. Dosages 
used and patient proﬁles were comparable across countries. CONCLUSIONS: 
Funding on top of DRG does not appear to increase drug usage, but contributes to 
early uptake. Health technology assessment conclusions inﬂuence utilization strongly. 
Payment by performance is associated with signiﬁcant development of drug penetra-
tion. The disparity of access for cancer patients raises the issue of associated outcome 
and equity.
PCN141
USING A DISEASE MANAGEMENT APPROACH IN A HEALTH 
TECHNOLOGY ASSESSMENT: A CASE STUDY
Walker JB1, Staﬁnski T1, McCabe C2, Menon D1
1University of Alberta, Edmonton, AB, Canada, 2University of Leeds, Leeds, UK
OBJECTIVES: Health technology assessments (HTA) typically compare the clinical 
beneﬁts and costs of a single candidate technology with an existing standard of care. 
Recently, some have argued that HTA should adopt a disease management approach 
in order to better reﬂect clinical practice, whereby the technology may simultaneously 
compete, complement or overlap with existing technologies at multiple points in the 
clinical pathway. Thus, the purpose of our study was to compare and contrast the 
disease management and traditional approaches in an HTA case study. METHODS: 
Markov models comparing photodynamic therapy (PDT) to esophagectomy for the 
treatment of Barrett’s esophagus with high-grade dysplasia were used to evaluate 
treatment cost and effectiveness. To investigate the traditional HTA approach, 
PDT was modeled as a standalone therapy. To investigate the disease management 
approach, PDT was modeled as the primary treatment with additional, secondary 
treatments (radiofrequency ablation and/or endoscopic mucosal resection) available 
in the event of PDT failure, reﬂecting local practice. RESULTS: PDT was less expen-
sive and more effective with respect to quality-adjusted life years (QALYs) than 
esophagectomy in all models. In contrast, PDT treatment resulted in more cancer 
cases than esophagectomy in all models. When comparing the two approaches to 
HTA, modeling PDT as a standalone therapy underestimated the incremental effective-
ness of PDT compared to esophagectomy (0.7 versus 1.0 QALYs) and overestimated 
the lifetime cancer incidence (5.1% versus 4.1%) and the total cost of treatment 
($21,000 versus $17,000). CONCLUSIONS: The disease management approach is 
more intensive than traditional HTA, requiring more research, data analysis and 
complex modeling. Using a disease management approach did not alter the favour-
ability of PDT with respect to esophagectomy. However, given the 20–30% difference 
observed in incremental effectiveness and cost between the two methodologies, it is 
possible that the approach taken could ultimately inﬂuence the outcome of a more 
difﬁcult decision.
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EVALUATING COMPARATIVE EFFECTIVENESS RESEARCH FOR 
ONCOLOGY IN THE US: AN ANALYSIS BASED ON LESSONS FROM 
HEALTH TECHNOLOGY ASSESSMENTS IN EUROPE
Patel P1, Roberts S2, Sparrowhawk K1, Ng-Haing J1
1PriceSpective LLC, London, UK, 2PriceSpective, BlueBell, PA, USA
OBJECTIVES: As part of health care reform, US policymakers are debating on 
whether or not to create a centralized comparative effectiveness research (CER) entity 
to improve the efﬁciency, quality and long-term sustainability of health care. If imple-
mented, cancer is likely to be among the recommended primary CER topics. In Europe, 
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there are established agencies that evaluate new pharmaceuticals to inform health care 
policy decisions (e.g., the HAS in France and NICE in the UK). This analysis will 
consider the strengths and weaknesses of European health technology bodies (HTA) 
and provide insight for the implementation of CER and how lessons learned from the 
UK and France might help improve efﬁciency and outcomes in oncology in the US. 
METHODS: Secondary research will be used to review how HTA bodies evaluate 
oncologics and assess their impact on market access. These countries were selected as 
they represent the extremes of HTA assessment in Europe. Findings from this research 
will then be contrasted against current market access in the US. RESULTS: While 
France evaluates new products on innovation and clinical value the UK largely bases 
market access decisions on cost-effectiveness. Consequently, many new oncology 
agents available in France have been denied funding in the UK. Meanwhile, insured 
Americans have relatively open access. CONCLUSIONS: Cancer remains the second 
leading cause of death in the US and is a growing health care burden. Therefore better 
informed policy decisions on the efﬁcient use of clinical services for oncology are 
critical. This analysis suggests that there is potential for the US to optimize on the 
European experiences when considering the adoption of a CER tool for oncology 
drugs management. Speciﬁcally, if the US does adopt a formal CER entity, it may wish 
to avoid using NICE-like economic-based outcomes to change clinical practice, but 
and aim to play an advisory role to facilitate better informed strategic decisions 
(HAS-like).
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COST-EFFECTIVENESS OBSERVATIONS AND ONCOLOGY DRUG 
REIMBURSEMENT RECOMMENDATIONS IN CANADA BY THE JOINT 
ONCOLOGY DRUG REVIEW
Ciapanna CC1, Yunger S1, Shum D1, Milliken D1, Longo CJ2, Aissa F1
1Hoffmann-La Roche Limited, Mississauga, ON, Canada, 2McMaster University, Hamilton, 
ON, Canada
OBJECTIVES: In Canada, the interim Joint Oncology Drug Review (JODR) conducts 
health technology assessments for all oncology products and provides funding recom-
mendations to participating provinces. Summaries of these recommendations are 
publically available, however investigation of the potential factors that inﬂuence 
these decisions has not been conducted. Furthermore, the acceptable incremental 
cost-effectiveness ratio (ICER) used by the JODR has not been published. This 
analysis was conducted to assess the differences in the average ICER between the 
JODR’s positive and negative recommendations and determine the relative inﬂuence 
of cost-effectiveness evidence on decision-making. METHODS: A literature search 
for pharmacoeconomic data was conducted for all 24 drugs with cancer indications 
reviewed by the JODR and made publicly available between March 2007 and Decem-
ber 2009. Cost-effectiveness data was extracted and converted into Canadian cur-
rency (CAD) to provide an estimate for Canadian public payers. The JODR and 
Ontario Public Drug Plan (OPDP) recommendations and decisions were analyzed in 
the context of these ICER values. RESULTS: Cost-effectiveness literature was found 
for 18 of the 24 drugs and of those, only 15 had published ICER values. ICER 
values ranged from approximately CAD$10,000/QALY to CAD$127,000/QALY. 
The average ICER of those cancer drugs considered to be cost-effective by the JODR 
was CAD$44,269/QALY, whereas the ICER for drugs considered not cost-effective 
was CAD$75,882/QALY (p = 0.10). Furthermore, drugs that were recommended 
for funding had a lower ICER when compared to those that were not recommended 
for funding ($57,578 vs. $81,490/QALY, p = 0.50). CONCLUSIONS: These ﬁndings 
suggest that while the ICER may be an important factor in the JODR decision-
making process, a careful examination of all factors leading to ﬁnal reimbursement 
decisions is needed to fully understand the relative importance of the ICER. Further 
research is required to determine if there are differences in the application of the 
ICER in decision-making processes for oncology medications versus other disease 
areas.
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COMPARITIVE KNOWLEDGE OF BREAST SELF EXAMINATION IN 
MIDWIFERY AND NURSING STUDENTS IN ISLAMIC AZAD UNIVERSITY 
KARAJ BRANCH
Ashkvary P
Islamic Azad University Of Iran Karaj Branch, kARAJ, Tehran, Iran
BACKGROUND: Breast cancer is the most common type of cancer among women 
world wide ranking second in mortality from cancer. Bse is a screaning method that 
should be taught at an early age so as to educate women about the importance of 
early detection of breast cancer. OBJECTIVES: The aim of this study was to evaluate 
the level of knowledge of midwifery and nursing student regarding breast self –exami-
nation . METHODS: This study is descriptive on 23 midwifery and 69 nursing 
student.data collection tool was a questionnaire the included6 questions about demo-
graphic characteristics, and 14 question about knowledge breast self examination. 
Data analyzed by descriptive statistics. RESULTS: Our results show that the average 
age being (21–35),majo rity of them are single (%67/4)and (%29/3) twin. Our result 
showed no signiﬁcant differences in midwifery and nursing knowledge.(p > 5%). Our 
result showed the students of midwifery and nursing have mild knowledge. CONCLU-
SIONS: It seems that despite of the importance of the BSE in early diagnosis of breast 
cancer the majority of women have poor knowledge and practice about BSE.Based on 
the positive attitude of most women about BSE, it is that increasing the knowledge of 
women by education ways of breast cancer, especially BSE, this will be available by 
more attention of public health centers, TV and newspaper for increasing women 
awareness. Key word:breast,student,cancer,self examination.
PCN145
A COMPARISON OF PHYSICIAN AND PATIENT DECISION MAKING FOR 
FIRST VERSUS SECOND OPINIONS AMONG MEN WITH LOCAL STAGE 
PROSTATE CANCER
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OBJECTIVES: Expert groups recommend men with local stage prostate cancer seek 
second opinions before choosing a management option. The nature of the physician-
patient interaction and outcomes for second versus primary opinion visits are 
unknown. METHODS: Newly diagnosed local stage prostate cancer patients and 
physicians at urology practices in three states participated in a survey of patient and 
doctor decision making following biopsy but prior to initiating treatment. Physicians 
were asked about the clinical status of the patient’s cancer, treatments discussed and 
recommended, and what factors most inﬂuenced the physician’s treatment 
recommendation(s). Patients were asked their treatment preference and what treat-
ments the physician recommended. RESULTS: A total of 238 local stage prostate 
cancer patients and their urologists completed surveys. Patient characteristics were: 
47% aged 60–69; 71% white, 16% black, 11% Hispanic; 49% had an income of 
≥$75,000. Ninety-ﬁve men were presenting for a primary consultation; 143 men were 
presenting for a second opinion. Among the initial consultation group, 64% were 
considering/planning a prostatectomy. Among the group seeking a second opinion, 
83% were considering/planning a prostatectomy. Of those seeking a primary recom-
mendation 59% had low risk disease, similar to the second opinion setting (54%). 
For low risk patients (primary vs. secondary opinions, respectively), physicians recom-
mended surgery for 80%/90%, external radiation for 38%/16%, seeds for 52%/14%, 
and watchful waiting for 25%/16%. In multivariate analysis, during an initial con-
sultation physicians recommended 0.51 more treatments (standard error 0.12, p < 
0.001) and were half as likely to consider the patient’s preference as a factor in their 
recommendations (OR 0.49, CI 026–0.95). CONCLUSIONS: Patient preferences and 
physician recommendations differ substantially in secondary versus primary opinion 
settings. In secondary opinion visits, patients are more likely to want prostatectomy 
and physicians are more likely to consider patient preference when making recom-
mendations. This is true even for men with low risk disease.
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REAL WORLD DATA ON MULTIPLE MYELOMA (MM) TREATMENT IN 
BRAZIL: GUIDANCE FOR THE PRIVATE HEALTH CARE SYSTEM (PHS)
Alves AFF, Castro APC, Clark LGO, Santos FS, Clark O, Engel T, Pegoretti B
Evidencias, Campinas, Brazil
OBJECTIVES: New treatments in oncology frequently imply in higher costs. Histori-
cally there is a lack of statistical data on cancer treatments in PHS in Brazil. Higher 
costs combined to lack of information may result in waste of resources. We present 
here real world data (RWD) on MM treatment collected from a dedicated database 
of cancer treatments Evidencias® (www.evidencias.com.br). METHODS: Between 
November of 2007 and October 2009 we retrieved all patients with MM registered 
on Evidencias®. Anthropometric data, staging, types of treatment, duration, and cost 
of chemotherapy and adjunctive therapies (AT) such as antiemetics, erythropoietin, 
colony stimulating factors and bisphosphonates were extracted. RESULTS: We identi-
ﬁed 98 patients (53% women and 47% men). The mean body surface area (BSA) 
was1.73 m2. Staging was stratiﬁed as follows: 21% Stage I, 8% stage II and 54% 
stage III. In 17% of the cases stage information was unavailable. Total cost of drugs 
was US$1,709,404.50. Chemotherapy drugs represented US$1,214,275.03 (71%) of 
which 98% (US$1,192,849.98) were due to the use of Bortezomib and 29% 
(US$495,129.46) to AT. Bortezomib was present in 57% of the treatments either 
isolated (42%) or combined to other chemotherapy (15%). Cyclophosphamide was 
used in 20% of the treatments, Doxorubicin in 18% and Melphalan in 5%. Mean 
duration of treatment was 3.9 cycles of chemotherapy. CONCLUSIONS: Real world 
data although a fundamental tool to guide health care providers in the correct alloca-
tion of resources, is still rare in Brazil e Latin America. Bortezomib is used in 57% of 
MM treatments but represents 98% of chemotherapy costs.
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CHARACTERISTICS OF POSTMENOPAUSAL WOMEN INITIATING 
RALOXIFENE BEFORE AND AFTER APPROVAL OF INVASIVE BREAST 
CANCER RISK REDUCTION INDICATIONS
Foster S1, McQuarrie N2, Coleman A1, Whangbo A2, Miller LA1, Bhujabal S2, Gilra N2
1Eli Lilly and Company, Indianapolis, IN, USA, 2ZS Associates, New York, NY, USA
OBJECTIVES: This study evaluated characteristics of postmenopausal women (PMW) 
who initiated raloxifene (RLX) therapy before and after the approval of the invasive 
breast cancer (BC) risk reduction (IBCRR) indications. METHODS: PMW 50 years 
and older with at least one claim for RLX in 2005–2008 and continuous enrollment 
over the study period (Jan 2004-Dec 2008) were identiﬁed in a large national com-
mercial and Medicare supplemental claims database. PMW on RLX were evaluated 
based on clinical and demographic variables such as age, provider specialty, fractures, 
bone mineral density (BMD) screening, Chronic Disease Score (CDS), family history 
of BC, and mammograms 12 months before and 12 months after the IBCRR indication 
